Estrogen receptor (ESR1) mRNA expression and benefit from tamoxifen in the treatment and prevention of estrogen receptor-positive breast cancer - PubMed (original) (raw)
. 2011 Nov 1;29(31):4160-7.
doi: 10.1200/JCO.2010.32.9615. Epub 2011 Sep 26.
Gong Tang, Katherine L Pogue-Geile, Joseph P Costantino, Frederick L Baehner, Joffre Baker, Maureen T Cronin, Drew Watson, Steven Shak, Olga L Bohn, Debora Fumagalli, Yusuke Taniyama, Ahwon Lee, Megan L Reilly, Victor G Vogel, Worta McCaskill-Stevens, Leslie G Ford, Charles E Geyer Jr, D Lawrence Wickerham, Norman Wolmark, Soonmyung Paik
Affiliations
- PMID: 21947828
- PMCID: PMC3208536
- DOI: 10.1200/JCO.2010.32.9615
Estrogen receptor (ESR1) mRNA expression and benefit from tamoxifen in the treatment and prevention of estrogen receptor-positive breast cancer
Chungyeul Kim et al. J Clin Oncol. 2011.
Abstract
Purpose: Several mechanisms have been proposed to explain tamoxifen resistance of estrogen receptor (ER) -positive tumors, but a clinically useful explanation for such resistance has not been described. Because the ER is the treatment target for tamoxifen, a linear association between ER expression levels and the degree of benefit from tamoxifen might be expected. However, such an association has never been demonstrated with conventional clinical ER assays, and the ER is currently used clinically as a dichotomous marker. We used gene expression profiling and ER protein assays to help elucidate molecular mechanism(s) responsible for tamoxifen resistance in breast tumors.
Patients and methods: We performed gene expression profiling of paraffin-embedded tumors from National Surgical Adjuvant Breast and Bowel Project (NSABP) trials that tested the worth of tamoxifen as an adjuvant systemic therapy (B-14) and as a preventive agent (P-1). This was a retrospective subset analysis based on available materials.
Results: In B-14, ESR1 was the strongest linear predictor of tamoxifen benefit among 16 genes examined, including PGR and ERBB2. On the basis of these data, we hypothesized that, in the P-1 trial, a lower level of ESR1 mRNA in the tamoxifen arm was the main difference between the two study arms. Only ESR1 was downregulated by more than two-fold in ER-positive cancer events in the tamoxifen arm (P < .001). Tamoxifen did not prevent ER-positive tumors with low levels of ESR1 expression.
Conclusion: These data suggest that low-level expression of ESR1 is a determinant of tamoxifen resistance in ER-positive breast cancer. Strategies should be developed to identify, treat, and prevent such tumors.
Conflict of interest statement
Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.
Figures
Fig 1.
CONSORT diagram. NSABP, National Surgical Adjuvant Breast and Bowel Project; RT-PCR, reverse transcriptase polymerase chain reaction. (*) Included in analysis.
Fig 2.
Quantitative estrogen receptor expression by reverse transcriptase polymerase chain reaction and distant recurrence at 10 years. Each Kaplan-Meier plot represents tamoxifen and placebo arms of patients diagnosed with tumors that express (A) low, (B) middle, and (C) high tertile levels of ESR1 mRNA. HR, hazard ratio.
Fig 3.
RNA and protein measurement of estrogen receptor (ER) and clinical outcome. (A) Rate of distant recurrence at 10 years as a function of quantitative ER by reverse transcriptase polymerase chain reaction (RT-PCR) in the placebo (blue line) and tamoxifen (gold line) groups. Solid lines are estimates, and dashed lines are 95% confidence bands. (B) Log-hazard ratio against the mean versus ESR1 mRNA on the basis of 290 patients randomly assigned to tamoxifen. Dashed lines are 95% confidence bands. (C) Log-hazard ratio against the mean versus ER by ligand binding assay (LBA) on the basis of 1,345 patients randomly assigned to tamoxifen, with ER by LBA less than 450 fmol/mg. (D) Log-hazard ratio against the mean versus ER by immunohistochemistry (IHC) on the basis of 177 patients randomly assigned to tamoxifen. DRFI, distant recurrence–free interval.
Fig 4.
Results of microarray gene expression analysis of National Surgical Adjuvant Breast and Bowel Project (NSABP) Breast Cancer Prevention Trial (P-1) estrogen receptor (ER) –positive cancer events. (A) Volcano plot of the results of t test for differences of expression levels of all filtered genes (N = 7,743) from Agilent array (Agilent Technologies, Santa Clara, CA) between ER-positive invasive cancer events that occurred initially in the tamoxifen versus the placebo arm from NSABP P-1 (N = 84). The x axis represents log (fold difference between two phenotypes); the y axis represents log (P value). Each spot represents a gene. Locations of the ER gene probe (ie, ESR1) and of GRFA1 are noted. (B) Scattergram of normalized ESR1 mRNA levels of ER-positive invasive breast cancer events from the NSABP P-1 according to treatment assignment (N = 84). Note the absence of tumors with high levels of ESR1 mRNA in the tamoxifen arm. Horizontal bars represent mean with standard errors. P value for the difference was less than .001. Data are plotted in a natural scale to better demonstrate the differences in higher expression level data range.
Similar articles
- A candidate molecular signature associated with tamoxifen failure in primary breast cancer.
Vendrell JA, Robertson KE, Ravel P, Bray SE, Bajard A, Purdie CA, Nguyen C, Hadad SM, Bieche I, Chabaud S, Bachelot T, Thompson AM, Cohen PA. Vendrell JA, et al. Breast Cancer Res. 2008;10(5):R88. doi: 10.1186/bcr2158. Epub 2008 Oct 17. Breast Cancer Res. 2008. PMID: 18928543 Free PMC article. - Estrogen receptor status of primary breast cancer is predictive of estrogen receptor status of contralateral breast cancer.
Swain SM, Wilson JW, Mamounas EP, Bryant J, Wickerham DL, Fisher B, Paik S, Wolmark N. Swain SM, et al. J Natl Cancer Inst. 2004 Apr 7;96(7):516-23. doi: 10.1093/jnci/djh097. J Natl Cancer Inst. 2004. PMID: 15069113 - Genomic index of sensitivity to endocrine therapy for breast cancer.
Symmans WF, Hatzis C, Sotiriou C, Andre F, Peintinger F, Regitnig P, Daxenbichler G, Desmedt C, Domont J, Marth C, Delaloge S, Bauernhofer T, Valero V, Booser DJ, Hortobagyi GN, Pusztai L. Symmans WF, et al. J Clin Oncol. 2010 Sep 20;28(27):4111-9. doi: 10.1200/JCO.2010.28.4273. Epub 2010 Aug 9. J Clin Oncol. 2010. PMID: 20697068 Free PMC article. - The association between type of endocrine therapy and development of estrogen receptor-1 mutation(s) in patients with hormone-sensitive advanced breast cancer: A systematic review and meta-analysis of randomized and non-randomized trials.
Najim O, Seghers S, Sergoynne L, Van Gaver H, Papadimitriou K, Wouters K, Trinh XB, Huizing MT, Tjalma W. Najim O, et al. Biochim Biophys Acta Rev Cancer. 2019 Dec;1872(2):188315. doi: 10.1016/j.bbcan.2019.188315. Epub 2019 Oct 21. Biochim Biophys Acta Rev Cancer. 2019. PMID: 31647985 Review. - Tamoxifen--an update on current data and where it can now be used.
Wickerham L. Wickerham L. Breast Cancer Res Treat. 2002 Oct;75 Suppl 1:S7-12; discussion S33-5. doi: 10.1023/a:1020353530963. Breast Cancer Res Treat. 2002. PMID: 12353826 Review.
Cited by
- Key target genes related to anti-breast cancer activity of ATRA: A network pharmacology, molecular docking and experimental investigation.
Manoochehri H, Farrokhnia M, Sheykhhasan M, Mahaki H, Tanzadehpanah H. Manoochehri H, et al. Heliyon. 2024 Jul 9;10(14):e34300. doi: 10.1016/j.heliyon.2024.e34300. eCollection 2024 Jul 30. Heliyon. 2024. PMID: 39108872 Free PMC article. - Hormone receptor mRNA and protein levels as predictors of premenopausal tamoxifen benefit.
Engström T, Ekholm M, Fernö M, Lundgren C, Nordenskjöld B, Stål O, Bendahl PO, Tutzauer J, Rydén L. Engström T, et al. Acta Oncol. 2024 Apr 8;63:125-136. doi: 10.2340/1651-226X.2024.19655. Acta Oncol. 2024. PMID: 38587062 Free PMC article. Clinical Trial. - Patient-specific analysis of co-expression to measure biological network rewiring in individuals.
Wei L, Xin Y, Pu M, Zhang Y. Wei L, et al. Life Sci Alliance. 2023 Nov 17;7(2):e202302253. doi: 10.26508/lsa.202302253. Print 2024 Feb. Life Sci Alliance. 2023. PMID: 37977656 Free PMC article. - Breast cancers with high proliferation and low ER-related signalling have poor prognosis and unique molecular features with implications for therapy.
Licata L, Barreca M, Galbardi B, Dugo M, Viale G, Győrffy B, Karn T, Pusztai L, Gianni L, Callari M, Bianchini G. Licata L, et al. Br J Cancer. 2023 Dec;129(12):2025-2033. doi: 10.1038/s41416-023-02477-7. Epub 2023 Nov 7. Br J Cancer. 2023. PMID: 37935787 Free PMC article. - Tamoxifen-predictive value of gene expression signatures in premenopausal breast cancer: data from the randomized SBII:2 trial.
Lundgren C, Tutzauer J, Church SE, Stål O, Ekholm M, Forsare C, Nordenskjöld B, Fernö M, Bendahl PO, Rydén L. Lundgren C, et al. Breast Cancer Res. 2023 Sep 29;25(1):110. doi: 10.1186/s13058-023-01719-z. Breast Cancer Res. 2023. PMID: 37773134 Free PMC article.
References
- Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomized trials. Lancet. 2005;365:1687–1717. - PubMed
- Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998;90:1371–1388. - PubMed
- Clarke R, Liu MC, Bouker KB, et al. Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling. Oncogene. 2003;22:7316–7339. - PubMed
- Bryant J, Fisher B, Gunduz N, et al. S-phase fraction combined with other patient and tumor characteristics for the prognosis of node-negative, estrogen-receptor-positive breast cancer. Breast Cancer Res Treat. 1998;51:239–253. - PubMed
- Fisher B, Redmond C, Brown A, et al. Influence of tumor estrogen and progesterone receptor levels on the response to tamoxifen and chemotherapy in primary breast cancer. J Clin Oncol. 1983;1:227–241. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- U10-CA-69651/CA/NCI NIH HHS/United States
- U10-CA-37377/CA/NCI NIH HHS/United States
- U24-CA-114732/CA/NCI NIH HHS/United States
- U10 CA069651/CA/NCI NIH HHS/United States
- U10 CA069974/CA/NCI NIH HHS/United States
- U10 CA037377/CA/NCI NIH HHS/United States
- U10 CA012027/CA/NCI NIH HHS/United States
- U24 CA114732/CA/NCI NIH HHS/United States
- U10-CA-69974/CA/NCI NIH HHS/United States
- U10-CA-12027/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous